IP Library Granted Patent US 9,802,948
Granted Patent B2
US 9,802,948 · App. 15/389,564 · Granted Oct 31, 2017

Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics

Inventors: Ulla Hansen (Bedford, MA); Scott Schaus (Boston, MA); Trevor Grant (Vernon, CT); Joshua Bishop (Belmont, MA); John Kavouris (Pittsburgh, PA); Lisa M. Christadore (Brighton, MA)
Assignee: TRUSTEES OF BOSTON UNIVERISTY
C07D491/056C07D215/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,802,948
App. No.
15/389,564
Granted
Oct 31, 2017
Kind
B2
Abstract

The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III′) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.

Claims (17)

1. A compound of formula (III′), wherein the Formula (III′) has the structure:

wherein:

R 1′ is an aryl substituted with at least one C 1 -C 6 alkoxyl and at least one di(C 1 -C 24 alkyl)amino, halogen or C 2 -C 8 alkenyl, wherein the substituted aryl can be optionally further substituted with halogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 heteroalkyl, di(C 1 -C 24 alkyl)amino or combinations thereof;

R 2 and R 3 are hydrogen or R 2 and R 3 together form a second bond between the carbons to which they are attached;

R 4 is hydrogen;

R 5 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;

R 6 and R 7 are each independently selected from the group consisting of hydrogen, F, Br, Cl and I;

R 10 and R 11 are each independently selected from the group consisting of hydrogen, F, Br, Cl, and I;

or enantiomers, prodrugs, derivatives, and pharmaceutically acceptable salts thereof, and

wherein the compound is capable of inhibiting late SV40 factor (LSF).

2. The compound of claim 1 , wherein R 1′ is a phenyl substituted with at least one C 1 -C 6 alkoxyl and at least one di(C 1 -C 24 alkyl)amino, halogen or C 2 -C 8 alkenyl.

3. The compound of claim 2 , wherein R 1′ is

wherein R 21 is C 1 -C 6 alkyl; R 22 and R 23 are independently selected C 1 -C 24 alkyl; R 24 is halogen; and R 25 is C 2 -C 8 alkenyl.

4. The compound of claim 3 , wherein R 1′ is

5. The compound of claim 1 , wherein the compound is selected from the groups consisting of

6. The compound of claim 1 , wherein the compound is FQI-34.

7. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient or carrier.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 13, 2025
From: BOSTON UNIVERSITY CHARLES RIVER CAMPUS
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 070794/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2017
From: HANSEN, ULLA; SCHAUS, SCOTT; GRANT, TREVOR; BISHOP, JOSHUA; KAVOURIS, JOHN; CHRISTADORE, LISA M.
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 043630/0509 →
Continuity (4)
Continuation In Part 15337584 · Oct 28, 2016
Continuation In Part 13879106
Provisional Application 61392607 · Oct 13, 2010
Related Publication 20170107227A1 · Apr 20, 2017